Objective: To determine whether a decline in cued recall is observable in the preclinical stage of Alzheimer disease (AD) in clinically normal older adults with elevated b-amyloid (Ab) burden on PET imaging.
Alzheimer disease (AD) includes a preclinical stage in which individuals exhibit elevated b-amyloid many years before dementia.
1,2 Identifying memory tests sensitive to the earliest signs of AD is vital as research and clinical care move toward earlier detection and intervention. 3 Traditional list-learning memory tests may be confounded by non-AD memory changes related to depression, inattention, or other dementias. 4 Tests of associative memory with semantic cueing such as the Free and Cued Selective Reminding Test (FCSRT) 5, 6 are particularly useful in identifying memory decline among patients with AD dementia. 7, 8 The FCSRT improves initial learning by providing a strategy: pairing the word to be remembered (e.g., grapes) with a semantic cue (e.g., fruit) to maximize learning and recall. 9 Failure at the stage of cued recall is particularly suggestive of a temporolimbic amnesia, has long-standing AD diagnostic utility, and was recommended by an International Working Group as a criterion for the diagnosis of AD. 7, 10 A recent study confirmed that decrements in cued recall had a greater association with AD pathology (CSF Ab 1-42 /tau ratios) among patients with mild cognitive impairment compared with other memory measures. 11 To determine whether declines in cued memory are associated with disease processes even earlier in the AD trajectory, i.e., in preclinical AD, we examined longitudinal memory performance in clinically normal (CN) older adults with and without high amyloid burden (Ab 1/2 on Pittsburgh compound B [PiB]-PET) at baseline. We were interested in whether Ab 1 status increased risk for cued memory decline and whether cued memory decline was associated with clinical progression.
METHODS Sample characteristics. CN individuals in the
Harvard Aging Brain Study were initially enrolled in September 2010, and recruitment is ongoing. At baseline, participants were deemed CN by global Clinical Dementia Rating (CDR) 12 score of 0, scores above education-adjusted cutoffs on Logical MemoryIIa (http://www.adni-info.org/), and normal performance on the Mini-Mental State Examination (score .25).
13,14 Exclusion criteria included a history of alcohol/drug abuse, head trauma, and current serious medical/psychiatric illness.
Standard protocol approvals, registrations, and participant consents. PiB-PET data were processed as distribution volume ratio images (40-to 60-minute interval, cerebellar gray reference). Mean PiB values were extracted from cortical regions that exhibit elevated PiB burden in patients with AD. 17 Dichotomization into Ab 1/2 groups was determined with a gaussian mixture modeling approach (cutoff value 5 1.20).
18
MRI data acquisition and analysis. Participants underwent MRI (Siemens Trio-TIM 3T scanner; 12-channel phased-array whole-head coil). High-resolution 3-dimensional T1-weighted multi-echo magnetization-prepared, rapid-acquisition gradient echo anatomic images were collected: repetition time 5 2,200 milliseconds; multi-echo echo times 5 1.54, 3.36, 5.18, and 7 milliseconds; flip angle 5 78; 34 acceleration; and 1.2 3 1.2 3 1.2-mm voxels. Hippocampus volume was labeled with FreeSurfer version 5.1, collapsed across hemispheres, and adjusted for estimated total intracranial volume.
Neuropsychological tasks. Participants underwent annual neuropsychological testing. We focus on the FCSRT for the aforementioned reasons. 11, 19 The FCSRT 6 is a multimodal associative memory measure; it pairs a pictured object with a semantic category to enhance encoding and includes immediate recall in the study phase to enhance retrieval (pictured object with a semantic category 1 immediate recall). In the study phase, participants learn 16 object-category pairs, presented 4 per card. The examiner names a category (e.g., fruit), and the participant is required to name the corresponding pictured object (e.g., grapes). If the participant fails to name the item with a cue, the participant is shown the card and "reminded" of the object. In the testing phase, the examiner asks the participant to recall all 16 objects (free recall [FR] ). For those items not freely recalled, the semantic cue is provided (cued recall). This procedure is repeated 3 times, with a 20-second distracter task between trials. Two scores are generated; the latter is our focus: FR is the sum of items freely recalled across 3 trials (of 48 items), and total recall (TR) is the sum of FR and cued recall across 3 trials (of 48 items). Although TR is the sum across FR and cued recall, items recalled freely are assumed to have been successfully recalled with a cue, and TR is considered a measure of cueing. Three equivalent stimulus versions were administered in the A-B-C-A-B-C pattern. 20 Participants also completed verbal fluency (F-A-S) annually.
Neuropsychological testing was administered by trained raters. However, early in the study, we discovered that one rater was misadministering TR. Twenty-two baseline administrations were compromised and treated as missing data. To address potential bias, we took 2 approaches: repeating all analyses excluding all baseline data and treating year 1 as baseline for those 22 participants with misadministered protocols. The results of these analyses were consistent with those completed on the entire dataset, described below. Age, sex, education, and their interactions with time (measured with respect to each participant's baseline testing session) were modeled as covariates. All models included a random intercept for each participant. These same models using continuous PiB were repeated within the Ab 1 group alone to determine whether higher accumulation above the 1.2 distribution volume ratio threshold was associated with greater FR or TR decline. Finally, given the limited variance observed in TR among CN individuals and the subsequent nonnormal residuals for the LMM of TR, survival analyses treating TR decline as an event in Ab 1/2 were subsequently completed (see below).
Interaction of amyloid status and hippocampal volume on longitudinal memory performance. Cued memory has been hypothesized to be particularly mediated by the hippocampus, 22 in contrast to FR, which may be more dependent on executive (i.e., frontal lobe) retrieval mechanisms. 23 To assess differential interactions between Ab and hippocampal volume on FR vs cued recall, hippocampal volume was added as a covariate to the LMM (described above). To explore whether Ab-related decline in FR is mediated by executive control mechanisms, we repeated the LMM with verbal fluency as a time-varying covariate.
Early vs late indicators of Ab-related memory decline. To determine at which year FR vs TR differed between Ab 1 and Ab 2 , we completed 2 mixed models of repeated measures using baseline performance and age as covariates, with a compound symmetric correlation structure and heterogeneous variance. 24 The mixed model of repeated measures analysis treats time as an ordinal variable, allowing examination of differences at each time point without assuming a linear trajectory.
Quantifying risk of cued memory decline and clinical progression. Cox proportional hazards models were then used to separately estimate the risk of Ab positivity on cued memory decline. 25 TR can be treated as a categorical variable because decline from the maximum score of 48 is infrequent (e.g., occurs in z20% of observations) and established cutoffs are available. For example, TR of #44/48 correctly classified 97% of participants with dementia, 26 and likewise, scoring #46/48 indicated a 5.6-fold increased risk of dementia diagnosis. 27 We examined decline corresponding to specific cutoffs (i.e., #47, 46, 45, and 44). Cox regression analyses were completed to determine the risk of TR decline to each cutoff separately in Ab 1/2 individuals with 48/48 in TR at baseline (n 5 215, 78% of sample, equal distribution of Ab 1/2 groups to complete sample). To confirm these analyses while including participants regardless of baseline performance, logistic regression was performed to determine the proportion of participants below cutoffs by group over a 3-year interval (i.e., length of an average clinical trial).
Ab 1 participants were further examined on TR with the use of the published cutoff of #46.
27 Ab 1 participants who scored #46 at any point over 3 years were grouped as low performers. They were compared to Ab 1 typical performers on baseline demographics, hippocampal volume, continuous levels of PiB, and clinical progression (defined as a global CDR score of 0.5 for a minimum of 2 sequential years).
RESULTS
The sample included 276 participants of an initial 381 recruited; they were followed up for 3.6 6 1.2 years (range 1-5 years). Twenty-three participants have withdrawn; 2 were lost to followup; and 6 are deceased. At baseline, Ab 1 individuals were older than Ab 2 individuals (table 1) and performed worse on the Mini-Mental State Examination (p 5 0.043); however, this difference was no longer significant when controlled for age (F 1,273 5 1.65, p 5 0.200). There were no group differences in education, sex, or baseline memory performance. Better FR was associated with younger age (p 5 0.002), female sex (p , 0.0001), and higher education (p 5 0.028). There was no relationship between these demographic factors and TR (table e-1). Quantifying risk of cued memory decline and clinical progression. Among the participants who scored 48/ 48 on TR at baseline (n 5 215), the Ab 1 group was more likely to decline at each cutoff (figure). The Ab 1 group was 1.63 times more likely to score #47 compared with the Ab 2 group, 3.55 times more likely to score #46, 7.38 times more likely to score #45, and 7.93 times more likely to score #44 (figure) . A similar pattern was observed when the proportion of participants were examined who scored below each of these cutoffs regardless of their baseline performance (table e-3). (table 3) . DISCUSSION In a large sample of well-characterized CN older adults, Ab 1 participants were at least 3 times more likely to decline on a sensitive indicator of cued memory. Although cued memory decline occurred infrequently, it was much more prevalent in the Ab 1 group: 37% of the Ab 1 participants scored #46/48 on TR compared with 10% of the Ab 2 participants over the course of 3 years. Furthermore, low performance in TR (#46/48) among the Ab 1 group was associated with early functional decline, i.e., greater risk of progression to global CDR of 0.5 for 2 sequential years. These findings are consistent with other recent reports 21, 28, 29 showing longitudinal memory decline in Ab 1 CN older adults. Our findings exhibit a strong association between cued memory decline and Ab 1 status among CN older adults and link cued memory decline to clinical progression among initially CN older adults. Our results reaffirm the previously identified specificity of cued memory performance to AD biomarkers in patients with mild cognitive impairment and AD 11 but also indicate that this relationship is observable much earlier in the AD trajectory than previously hypothesized. In addition, our results suggest that cued memory decline may be particularly relevant in determining who is likely to be on the AD trajectory and at risk for imminent clinically meaningful decline, a subset of participants who are of great interest for secondary prevention trials. Finally, our study provides insight into the evolution of memory decline along the preclinical trajectory. While decline in TR may be more prevalent in Ab 1 individuals, related to hippocampal atrophy, and proximal to functional decline, decline in FR may be a marker sensitive to amyloidosis in earlier phases of preclinical AD.
Memory tests with AD diagnostic specificity are preferable, hence the increased interest in the FCSRT in the recent literature. 11, 19 We found that yearly Ab group effects were higher for the FCSRT (20.18 to 20.23 z scores) in comparison with recent reports (20.07 z scores) using different memory tests. 21 This aligns with other work showing the superior AD biomarker specificity 11 and accuracy for diagnostic risk for AD dementia of the FCSRT. 19, 30 On the FCSRT, learning is fully supported; i.e., it is enhanced by providing a visual stimulus, associating the word with a semantic category, and requiring the participant to identify and name the word pictured. This type of learning paradigm is inherently different from most list-learning tasks in which the participant is left to his or her own devices to develop a strategy (or not), and thus performance is confounded by more executive control-type processes. 9 Ab 2 participants may benefit to a greater extent from the built-in strategy of the FCSRT than Ab 1 participants 31 given that early AD processes may selectively impair temporolimbic regions and that the combination of encoding a novel association and its semantic nature 30,32 may be particularly vulnerable to early AD pathology.
We focused on the published cutoff of 46/48 on TR, 27 but our findings highlight a stepwise increase in risk of the Ab 1 group, dropping to 47 (hazard ratio 5 1.63), to 46 (hazard ratio 5 3.55), to 45 (hazard ratio 5 7.38), etc. Among our CN population, these declines become increasingly rare, but this pattern of increasing risk highlights the meaningfulness of seemingly small declines. It suggests that performance below these cutoffs should be worrisome for progressive memory decline.
The stronger relationship between hippocampal atrophy and decline in TR compared with FR supports the literature pinpointing cued memory decline as "amnesia of the hippocampal type" and specific to AD. 8, 33 However, our results suggest that FR also captures Ab-related decline, potentially at an earlier point within the preclinical trajectory. More specifically, TR decline was driven by Ab 1 individuals who also showed evidence of hippocampal atrophy, emerged robustly in year 4, and was associated with clinical progression, while Ab 1/2 group differences for FR emerged in year 2 and were not diminished when controlling for verbal retrieval skills. Some Ab 1 individuals may be harboring sufficient pathology to exhibit reduced FR, perhaps as a result of Ab influence on synaptic function, but are not yet at the stage of neurodegeneration where TR is affected. Alternatively, having a smaller hippocampus may put individuals at greater risk of cued memory decline in the setting of high amyloid.
Another more compelling explanation for why decline in FR may be an early marker is that Ab 1 CN individuals are having particular difficulty at the stage of memory encoding rather than storage. Other studies have shown that initial learning 31, 34 declines before delayed recall in the AD trajectory, and fMRI studies show differential activation in associative encoding in Ab 1 compared with Ab 2 CN older adults. 35, 36 Interestingly, our results do not indicate that high levels of amyloidosis above the Ab 1 threshold are associated with greater rates of cognitive decline for FR or cued recall. Thus, recruiting superthreshold Ab 1 individuals for secondary prevention trials may not increase the degree of cognitive change observed over a time-limited trial.
Our study also highlights limitations of the FCSRT. The task can be difficult to administer, and raters require sufficient training. Given the pronounced ceiling effect and limited variance observed in TR among CN, LMM is unlikely the ideal statistical technique to examine change in TR over time. Timeto-event analyses such as the survival analysis also incorporated may be more relevant for this measure, and future work should continue to explore TR cutoffs that inform risk of AD dementia among CN samples.
Identifying Ab 1 CN individuals most likely to progress with a cognitive measure is a cost-effective means of selectively recruiting participants at greatest risk of decline over a time-limited clinical trial. In terms of tracking decline, TR on the FCSRT 24 may prove to be an important component of the Preclinical Alzheimer Cognitive Composite 19 outcome measure used in ongoing prevention trials. 37 Despite the high specificity of cued memory decline to amyloidosis, its infrequent occurrence raises the possibility that it be used in tandem with additional sensitive measures such as FR or metrics of subjective cognitive decline. 38 The cued memory decline cognitive phenotype may be particularly effective in identifying CN individuals on the AD trajectory at greatest risk of clinical progression. The combination of FR and TR may also be quite useful in measuring memory across the preclinical to prodromal AD trajectory, with decline in FR occurring with amyloidosis alone and decline in TR serving as an indicator of neurodegeneration associated with amyloidosis and predictive of functional progression.
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